In the CREDENCE trial [131], patients with T2D and albuminuric CKD were randomly assigned to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily, or a placebo. The gene discussed is SLC5A2; the disease is chronic kidney disease.